Company intelligence / Profile preview
Japan Tissue Engineering Co., Ltd.
- Ownership
- Private
- Employees
- ~211
- Development stage
- Commercial
Overview
Successfully commercialized multiple regenerative medicine products in Japan, including autologous cultured epidermis (JACE), autologous cultured cartilage (JACK), autologous cultured corneal epithelium, autologous cultured oral mucosal epithelium, and autologous cultured epidermis maintaining melanocytes. Recently received approval for expanding indication of autologous cultured cartilage for knee osteoarthritis in May 2025[1].
- Therapeutic areas
- GastroenterologyDermatologyRheumatologyOphthalmology
- Modalities
- Autologous cell therapiesTissue engineering
- Industry
- Biotech
Drug pipeline
12 assets11 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Japan Tissue Engineering Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Japan Tissue Engineering Co., Ltd..